Related Experiment Video
Updated: Aug 6, 2026
Method for Simultaneous fMRI/EEG Data Collection during a Focused Attention Suggestion for Differential Thermal Sensation
Published on: January 5, 2014
Hypnotic suggestibility as a moderator of treatment response in mild to moderate depression: an exploratory secondary
Julia Siewert1, Benno Brinkhaus1, Tatjana Tissen-Diabaté1
1Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Social Medicine, Epidemiology and Health Economics, Berlin, Germany.
Background:
Hypnotic suggestibility may moderate treatment outcomes, but evidence in depression is limited and inconsistent.
Objective:
This analysis examined whether baseline hypnotic suggestibility moderated changes in depressive symptoms over time and whether this effect differed between groups.
Methods:
This exploratory secondary analysis used data from the HypnoDeep trial, a randomized, controlled, pilot trial. Patients with mild to moderate depressive symptoms were randomized to group hypnosis, progressive muscle relaxation (PMR), or control. Hypnotic suggestibility was assessed with the Harvard Group Scale of Hypnotic Susceptibility, Form 5 (HGSHS-5:G) and the Creative Imagination Scale (CIS) at baseline. Depressive symptoms were measured at baseline and at 6 weeks using the Beck Depression Inventory-II. Linear mixed-effects models examined whether baseline suggestibility moderated depressive symptom changes and whether this association differed between groups, adjusting for age and sex. Separate models were estimated for HGSHS-5:G and CIS. A post hoc power analysis contextualized detectable effect sizes.
Results:
Ninety-four participants were included (mean age 39.2 years, SD 12.0; women: n = 67 [71.3%], men: n = 25 [26.6%], diverse: n = 2 [2.1%]). Baseline hypnotic suggestibility assessed with the HGSHS-5:G ranged from 0 to 5 (mean 2.9, SD 1.6), and CIS scores ranged from 2 to 35 (mean 17.6, SD 7.7). Baseline hypnotic suggestibility was not associated with differential change in depressive symptoms over time in the control group for either the HGSHS-5:G or the CIS, and there was no indication that this association differed in the hypnosis or PMR group compared with the control group (HGSHS-5:G: hypnosis β = 2.05, 95% CI -2.21 to 6.31, p = 0.350; PMR β = -0.97, 95% CI -5.14 to 3.20, p = 0.651; CIS: hypnosis β = 3.06, 95% CI -1.36 to 7.48, p = 0.179; PMR β = -0.44, 95% CI -4.49 to 3.61, p = 0.833). Post hoc power analysis indicated that complete-case group sizes were insufficient to reliably detect small-to-moderate associations.
Conclusion:
Exploratory analyses did not indicate that hypnotic suggestibility moderated changes in depressive symptoms across groups. Given limited statistical power, findings are preliminary and hypothesis-generating. Larger studies are needed to clarify treatment-response moderators.
Related Concept Videos
01:54The Placebo Effect
01:23Antidepressant Drugs: MAOIs and Other Agents
01:23Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...